Germani, M. M., Moretto, R., Hashimoto, T., Heinemann, V., Pietrantonio, F., Nakamura, Y., Stintzing, S., Bergamo, F., Muro, K., Venook, A. P., Weiss, L., Martini, G., Battaglin, F., Soeda, J., Blondeaux, E., Ciardiello, D., Lenz, H., Yoshino, T., Modest, D. P., Cremolini, C. (2026). Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS)
                    <i>RAS</i>
                    and
                    <i>BRAF</i>
                    wild-type (wt) and HER2− metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3550